These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18220279)

  • 41. Nonalcoholic steatohepatitis.
    Sanyal A
    Indian J Gastroenterol; 2001 Mar; 20 Suppl 1():C64-70. PubMed ID: 11293184
    [No Abstract]   [Full Text] [Related]  

  • 42. [Advances in the diagnosis of nonalcoholic steatohepatitis].
    Cai WM
    Zhonghua Gan Zang Bing Za Zhi; 2008 Nov; 16(11):811-2. PubMed ID: 19032861
    [No Abstract]   [Full Text] [Related]  

  • 43. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers.
    Mitry RR; De Bruyne R; Quaglia A; Hughes RD; Dhawan A
    Hepatology; 2007 Dec; 46(6):2047-8; author reply 2048. PubMed ID: 18046726
    [No Abstract]   [Full Text] [Related]  

  • 44. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonalcoholic fatty liver disease: from clinical recognition to treatment.
    Sevastianos VA; Hadziyannis SJ
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):59-79. PubMed ID: 19072371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A man with non alcoholic steatohepatitis].
    Tran A; Anty R
    Gastroenterol Clin Biol; 2003; 27(8-9):806-8. PubMed ID: 14586252
    [No Abstract]   [Full Text] [Related]  

  • 47. Nonalcoholic fatty liver disease.
    Hjelkrem MC; Torres DM; Harrison SA
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case report: nonalcoholic steatohepatitis in a teenage girl with type 2 diabetes.
    Nadeau K; Klingensmith G; Sokol RJ
    Curr Opin Pediatr; 2003 Feb; 15(1):127-31. PubMed ID: 12544284
    [No Abstract]   [Full Text] [Related]  

  • 49. [Pathology of nonalcoholic steatohepatitis].
    Jeen YM; Jin SY
    Korean J Hepatol; 2009 Jun; 15(2):122-30. PubMed ID: 19581764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Prashanth M; Ganesh HK; Vima MV; John M; Bandgar T; Joshi SR; Shah SR; Rathi PM; Joshi AS; Thakkar H; Menon PS; Shah NS
    J Assoc Physicians India; 2009 Mar; 57():205-10. PubMed ID: 19588648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonalcoholic fatty liver disease.
    Mofrad PS; Sanyal AJ
    MedGenMed; 2003 Apr; 5(2):14. PubMed ID: 14603113
    [No Abstract]   [Full Text] [Related]  

  • 52. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease.
    Nobili V; Alkhouri N; Alisi A; Ottino S; Lopez R; Manco M; Feldstein AE
    Clin Gastroenterol Hepatol; 2009 May; 7(5):575-9. PubMed ID: 19268270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
    Yilmaz Y; Atug O; Yonal O; Duman D; Ozdogan O; Imeryuz N; Kalayci C
    Med Sci Monit; 2009 Apr; 15(4):HY1-5. PubMed ID: 19333209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis.
    Schmilovitz-Weiss H; Niv Y; Pappo O; Halpern M; Sulkes J; Braun M; Barak N; Rotman Y; Cohen M; Waked A; Tur-Kaspa R; Ben-Ari Z
    J Clin Gastroenterol; 2008 Apr; 42(4):408-12. PubMed ID: 18277896
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease.
    Jin X; Ye YF; Chen SH; Yu CH; Liu J; Li YM
    Dig Liver Dis; 2009 Apr; 41(4):289-97. PubMed ID: 18922750
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An apoptosis biomarker for prediction of nonalcoholic steatohepatitis.
    Bantel H; Bahr MJ; Schulze-Osthoff K
    Hepatology; 2009 Sep; 50(3):991. PubMed ID: 19593820
    [No Abstract]   [Full Text] [Related]  

  • 58. Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated?
    Helling TS; Helzberg JH; Nachnani JS; Gurram K
    Surg Obes Relat Dis; 2008; 4(5):612-7. PubMed ID: 18226970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
    Choi SS; Diehl AM
    Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-alcoholic fatty liver disease pathogenesis: the present and the future.
    Petta S; Muratore C; Craxì A
    Dig Liver Dis; 2009 Sep; 41(9):615-25. PubMed ID: 19223251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.